Nasdaq

Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63rd ASH Annual Meeting

Data from patients with NHL treated in Phase 1 investigator-led study of GDA-201 demonstrates median duration of response of 16 months; safety outcomes consistent after two years Poster presentation ...
Business Wire

Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analysis for Omidubicel at 63 rd ASH Annual Meeting

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that two-year follow-up data for ...
Business Wire

Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET ® at Six Months

BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced ...
ascopubs.org

Disease management costs and healthcare resource utilization by progression health state among patients with previously untreated locally advanced or metastatic urothelial cancer.

First-line therapies analysis in advanced/metastatic urothelial carcinoma: Prognostic insights with propensity score analysis and RNA-seq. Enfortumab vedotin plus pembrolizumab in metastatic ...
ascopubs.org

Healthcare resource utilization (HRU) and costs among patients with Von Hippel-Lindau disease (VHL)-associated renal cell carcinoma (RCC): A retrospective administrative claims ...

Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC). This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary Cancers Symposium. This ...